Proteasome inhibition therapy: assessing the clinical implications in hematologic diseases.
This session addressed the use of proteasome inhibition therapy in multiple myeloma, specifically bortezomib. It also discussed various complications of multiple myeloma and cautions to be taken, specifically regarding osteolytic lesions and renal failure.
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001897:Boronic Acids / Q000009:adverse effects / Q000627:therapeutic use; D000069286:Bortezomib; D016903:Drug Monitoring / Q000451:nursing; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D009101:Multiple Myeloma / Q000628:therapy*; D009730:Nursing Assessment / Q000379:methods; D009859:Oncology Nursing / Q000379:methods*; D011480:Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D061988:Proteasome Inhibitors; D011719:Pyrazines / Q000009:adverse effects / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011480:Protease Inhibitors; D061988:Proteasome Inhibitors; D011719:Pyrazines; D000069286:Bortezomib